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The existing dogma is that protein medicines need to be produced in large factories, and then injected to the 
patient. We propose that miniature artificial inert factories can be injected to the patient, to produce a protein of 
interest directly in the diseased tissue. We engineered artificial cell-like particles with an autonomous capacity to 
synthesize protein drugs after receiving an external signal. The protein is tuned to the patient's needs based on 
a predetermined DNA code we incorporate inside the particles. This approach increases treatment efficiency 
and reduces adverse effects to healthy tissues. 
We developed a new T7-S30 based cell-free protein synthesis system, which contains all the transcription and 
translation machines and molecules required for protein production (Krinsky et al., PloS one 2016). This system 
was used to prepare liposomes that act as artificial cells, capable of producing proteins autonomously in 
response to a physical trigger. Functional enzymes (luciferase and tyrosinase) and fluorescent proteins (GFP) 
were successfully produced using the new cell-free protein synthesis system and inside the particles both in 
vitro and in vivo. In addition, we demonstrated the therapeutic capabilities of the protein producing particles by 
producing Pseudomonas exotoxin A, an extremely potent protein, for treating cancer. Applying the particles on 
4T1 cells (a triple-negative breast cancer cell-line) in vitro or injecting them into a 4T1-induced tumor in vivo, 
resulted in high cytotoxicity due to the effective production of the therapeutic protein inside the vesicles (Krinsky 
et al. Advanced Healthcare Materials, 2017).  
Synthetic cells serve as autonomous, trigger-able, artificial particles that produces a variety of proteins. This 
platform has promise to address a wide range of fundamental questions associated with protein synthesis in 






Figure 1 - the therapeutic platform. Onsite synthesis of protein medicines inside the body is achieved by 
encapsulation of all the transcription and translation factors required for protein production inside a 
liposome. (A)  Cell-free protein synthesis (CFPS) work flow. (B) Protein producing particle. (C) Personalized 
medicine; triggered protein production inside the patient’s body at the diseased tissue. 
